In This Article:
Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady growth and promising future earnings, identifying high-growth tech stocks like Nvidia can be crucial for investors seeking to capitalize on technological advancements and innovation-driven sectors.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 24.36% | 24.28% | ★★★★★★ |
Ardelyx | 21.09% | 55.29% | ★★★★★★ |
AVITA Medical | 33.20% | 51.87% | ★★★★★★ |
Bitdeer Technologies Group | 51.56% | 122.57% | ★★★★★★ |
TG Therapeutics | 29.48% | 43.58% | ★★★★★★ |
Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
Alnylam Pharmaceuticals | 21.62% | 56.70% | ★★★★★★ |
Blueprint Medicines | 23.52% | 55.88% | ★★★★★★ |
Travere Therapeutics | 30.52% | 61.89% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Sarepta Therapeutics
Simply Wall St Growth Rating: ★★★★★☆
Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $10.90 billion.
Operations: Sarepta focuses on discovering, developing, manufacturing, and delivering therapies for rare diseases, generating $1.64 billion in revenue from these activities.
Sarepta Therapeutics has demonstrated a robust trajectory in the biotech sector, with an annual revenue growth rate of 17.8% and earnings expected to surge by 29.9% annually. Notably, its commitment to innovation is underscored by substantial R&D investments, which are pivotal in driving forward its gene therapy solutions such as ELEVIDYS for Duchenne muscular dystrophy—a treatment that recently showcased positive Phase 3 results. These developments not only enhance Sarepta's market position but also signify potential long-term impacts on the treatment landscape for genetic disorders, reflecting both immediate gains and strategic depth in its pipeline.
-
Delve into the full analysis health report here for a deeper understanding of Sarepta Therapeutics.
-
Explore historical data to track Sarepta Therapeutics' performance over time in our Past section.
Cloudflare
Simply Wall St Growth Rating: ★★★★★☆
Overview: Cloudflare, Inc. is a cloud services provider offering various solutions to businesses globally, with a market capitalization of approximately $48.10 billion.